Value Investor
Start free

Bolt Biotherapeutics

BOLT on Nasdaq. Market value $7m.

Watch this stockFree. We tell you when something changes.

Should I look at this?

Look carefully before going further

Why it could be worth it

Nothing stands out yet.

What to watch out for

Read the warning sign in its own filings

This is not advice.

Compare with another stock

Who owns it

None of the long-term investors we follow own it. 23 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

4 investors own more than 5%.

  • at least 5.1%
    (filed with 1 related holder)
    Since 24 June 2026
  • at least 4.6%−2.1 pts
    (filed with 10 related holders)
    Since 24 February 2026
  • Vivo Panda Fund, L.P.
    Passive investor
    at least 3.8%
    (filed with 4 related holders)
    Since 31 December 2025
  • at least 3.5%0.0 pts
    (filed with 5 related holders)
    Since 30 September 2025

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 2 insiders bought $5,594 of shares on the open market. 3 sold $128,281.

  • Yonehiro Grant
    Chief Operating Officer
    Sold
    Date
    18 September 2026
    Shares
    6,850
    Price
    $3.24
    Value
    $22,169
  • Nemec Sarah
    Senior VP, Finance and PAO
    Sold
    Date
    18 September 2026
    Shares
    4,077
    Price
    $3.24
    Value
    $13,195
  • Quinn William P.
    President, CEO and CFO, Director
    Sold
    Date
    18 September 2026
    Shares
    9,132
    Price
    $3.24
    Value
    $29,555
  • Yonehiro Grant
    Chief Operating Officer
    Sold
    Date
    17 September 2026
    Shares
    4,909
    Price
    $3.32
    Value
    $16,290
  • Nemec Sarah
    Senior VP, Finance and PAO
    Sold
    Date
    17 September 2026
    Shares
    2,922
    Price
    $3.32
    Value
    $9,696
  • Quinn William P.
    President, CEO and CFO, Director
    Sold
    Date
    17 September 2026
    Shares
    6,545
    Price
    $3.32
    Value
    $21,718
  • Yonehiro Grant
    Chief Operating Officer
    Sold
    Date
    16 September 2026
    Shares
    1,417
    Price
    $3.77
    Value
    $5,348
  • Nemec Sarah
    Senior VP, Finance and PAO
    Sold
    Date
    16 September 2026
    Shares
    843
    Price
    $3.77
    Value
    $3,181
  • Quinn William P.
    President, CEO and CFO, Director
    Sold
    Date
    16 September 2026
    Shares
    1,889
    Price
    $3.77
    Value
    $7,129
  • Nemec Sarah
    Senior VP, Finance and PAO
    Bought
    Date
    5 June 2026
    Shares
    509
    Price
    $3.88
    Value
    $1,973

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

1 serious warning sign in Bolt Biotherapeutics’ filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 12 Mar 2026, plus the 10-Q filed 11 Aug 2026 and 3 later 8-Ks.

  • Doubt it can keep going

    Serious

    The company or its auditor warned it may not have enough money to last the next year.

    “The Company believes that this raises substantial doubt about its ability to continue as a going concern within one year after the issuance of the unaudited condensed consolidated financial statements.”
    Show the full paragraph
    The Company has incurred net losses and negative cash flows from operations since its inception, has an accumulated deficit $ 475.7 million and anticipates continuing to incur net losses for the foreseeable future. Under the Company's current plan, management believes its cash and cash equivalents and marketable securities of $ 18.1 million as of June 30, 2026 will not be sufficient for the Company to continue as a going concern for at least one year from the issuance date of these financial statements. The Company believes that this raises substantial doubt about its ability to continue as a going concern within one year after the issuance of the unaudited condensed consolidated financial statements.

    From the 10-Q filed 11 August 2026, Part I, Item 1. Financial Statements. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.